• LOGIN
  • SUBSCRIBE
  • FREE E-Newsletter/Product Bulletins

Annals of Long Term Care

  • Follow us on

Search

  • Home
  • ARCHIVES
    • Issues
    • Supplements/Webcasts
  • About Us
    • Mission Statement
    • Editorial Description
    • Editorial Board
    • Publishing Staff
    • Our Partners
    • AGS Affiliations
    • Reprints/Permissions
  • SUBMIT
    • Author Guidelines
    • Copyright Transfer Form
    • Author Disclosure Form
    • Submit Now
  • CONTACT
  • ADVERTISING
    • Print Rate Card
    • Online Rate Card
    • Classified Rate Card
    • Sales Contacts
  • Supplements/Special Projects
  • Journal News
  • WEBCASTS
    • Facing Postherpetic Neuralgia in LTC
    • Treatment for Postherpetic Neuralgia Pain
    • Case Study—LTC Patient Suffering from PHN

Q & A With the Expert on: Congestive Heart Failure

  • Thu, 9/10/09 - 12:04pm
  • 0 Comments
  • 2068 reads
Citation: 

Pages 19 - 20

Author(s): 

Wilbert S. Aronow, MD, FACC, FAHA, AGSF

Q: How should a 78-year-old woman with congestive heart failure (CHF) after myocardial infarction be treated?

Case Presentation

A 78-year-old functionally independent woman has a 10-year history of hypertension and dyslipidemia. She developed CHF after an acute myocardial infarction 3 months ago. She has a nonproductive cough when lying down and New York Heart Association (NYHA) class III symptoms (dyspnea with less than ordinary activity). Her current medications include furosemide 40 mg daily, ramipril 10 mg twice daily, rosuvastatin 20 mg daily, diltiazem CD 240 mg daily, and aspirin 81 mg daily.

Physical examination in her physician’s office reveals a blood pressure in the standing and sitting positions in the right brachial artery of 128/78 mm Hg and 130/80 mm Hg, respectively, and in the left brachial artery of 126/76 mm Hg and 128/78 mm Hg, respectively. The pulse is regular with a rate of 96 beats per minute. The respiratory rate is 20 per minute. The patient’s weight has increased 5 pounds over the past month, and she now weighs 130 pounds. Physical examination is normal except for a left ventricular third heart sound heard at the point of maximum apical impulse. The cardiac rhythm is regular with a ventricular rate of 98/minute.

Her fasting blood sugar, hemoglobin, hematocrit, blood urea nitrogen, serum creatinine, sodium, potassium, chloride, carbon dioxide, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides are normal. A 12-lead electrocardiogram shows sinus rhythm with a ventricular rate of 96/minute, an old Q-wave anterior myocardial infarction, and a QRS duration of 110 msec. A chest roentgenogram shows mild pulmonary vascular congestion. A 2-dimensional echocardiogram reveals a left ventricular ejection fraction (LVEF) of 37%.

How should this woman have her CHF managed?

A:Patients with pulmonary vascular congestion due to CHF may not have pulmonary rales heard at the lung bases. Of 50 patients with chronic CHF and a pulmonary capillary wedge pressure ≥ 22 mm Hg, 48 (96%) had a left ventricular third heart sound, 25 (50%) had increased jugular venous pressure, 8 (16%) had pulmonary rales, and 10 (20%) had peripheral edema.1

Ramipril, rosuvastatin, and aspirin should be continued as prescribed in this woman with CHF, a reduced LVEF, and prior myocardial infarction. The dose of furosemide should be increased to 60 mg daily. Salt restriction and use of diuretics are American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) class I indications for treating CHF.2 Treatment of hypertension and dyslipidemia and use of angiotensin-converting enzyme (ACE) inhibitors are also class I indications.2

Diltiazem should be stopped in this woman since it exacerbates CHF in patients with CHF and a reduced LVEF3 and increases mortality in patients with pulmonary congestion and a reduced LVEF after myocardial infarction.4 Calcium-channel blockers, nonsteroidal anti-inflammatory drugs, and most antiarrhythmic drugs should not be used in patients with CHF and a reduced LVEF.2

This patient needs the addition of a beta blocker such as metoprolol CR/XL or carvedilol to treat her CHF.2,5,6 Beta blockers should be initiated in a low dose such as carvedilol 3.125 mg twice daily or metoprolol CR/XL 12.5 mg daily in patients with NYHA class III or IV CHF or 25 mg daily in patients with NYHA class II CHF.7 The dose of beta blockers should be doubled at 2- to 3-week intervals, as tolerated, with the maintenance dose reached over 3 months. The maintenance dose should be metoprolol CR/XL 200 mg once daily or carvedilol 25 mg twice daily (50 mg twice daily if the patient weighs more than 187 pounds).7 During titration, the patient should be monitored for CHF symptoms, fluid retention, hypotension, and bradycardia. If there is worsening of symptoms, the dose of diuretics or ACE inhibitors should be increased.

References: 

1. Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 1989;61:884-888.

2. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53:1343-1382.

3. Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990;82:1954-1961.

4. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-392.

5. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2007.

6. Packer M, Coats AJ, Fowler MB, et al; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in chronic heart failure. N Engl J Med 2001;344:651-658.

7. Aronow WS. Treatment of heart failure with abnormal left ventricular systolic function in the elderly. In: Aronow WS, ed. Clinics in Geriatric Medicine on Heart Failure. Volume 23. Philadelphia, PA: Elsevier; 2007:61-81.

8. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Eng J Med 2002;347:1403-1411.

9. Ahmed A, Aronow WS, Fleg JL. Predictors of mortality and hospitalization in women with heart failure in the Digitalis Investigation Group trial. Am J Ther 2006;13:325-331.

10. Ahmed A, Aban IB, Weaver MT, et al. Serum digoxin concentration and outcomes in women with heart failure: A bi-directional effect and a possible effect modification by ejection fraction. Eur J Heart Failure 2006;8:409-419. Published Online: November 28, 2005.

image description image description
  • 1
  • 2
  • next ›
  • last »



Post new comment

  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
  • Use to create page breaks.

More information about formatting options

Image CAPTCHA
Enter the characters shown in the image.

LATEST NEWS

  • FDA Finally Approves Once-Weekly Type 2 Diabetes Treatment
    [Amylin] 1-31-12
  • FDA approves Voraxaze to treat patients with toxic methotrexate levels
    [FDA] 1-17-12
  • FDA approves first generic version of cholesterol-lowering drug Lipitor
    [FDA] 11-30-11
  • AHRQ Awards $34 Million To Expand Fight Against Healthcare-Associated Infections
    [AHRQ] 11-17-11
more »

Poll

Are nutritional supplements underutilized in long-term care?:

Classified/Recruitment Opportunities

  • Advertise Your Job Here
more »

ALTC Blogs

Getting the Most Out of Your Continuing Medical Education Classes

Neil Baum MD
2/8/12 | 0 Comments | 7 reads

February is American Heart Month

Alvin B Lin MD FAAFP
2/7/12 | 0 Comments | 26 reads

How to Create Collegiality in a Difference of Opinion: Part 2

Neil Baum MD
2/6/12 | 0 Comments | 35 reads
more »
banner banner banner banner banner
HMP Communications © 2012 HMP Communications
  • Home
  • About Us
  • Other Publications
  • Contact Us
  • Privacy Policy

HMP Communications LLC (HMP) is the authoritative source for comprehensive information and education servicing healthcare professionals. HMP’s products include peer-reviewed and non-peer-reviewed medical journals, national tradeshows and conferences, online programs and customized clinical programs. HMP is a wholly owned subsidiary of HMP Communications Holdings LLC. © 2012 HMP Communications